International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(24), С. 13613 - 13613
Опубликована: Дек. 19, 2024
This
longitudinal
study
examined
how
active
gastrointestinal
(GI)
cancer
types
affect
immune
responses
to
SARS-CoV-2,
focusing
on
the
ability
neutralize
Omicron
variants.
Patients
with
GI
(n
=
168)
were
categorized
into
those
hepatocellular
carcinoma,
hepatic
metastatic
cancer,
non-hepatic
and
two
control
groups
of
patients
without
underlying
liver
diseases.
Humoral
cellular
evaluated
before
after
antigen
exposures.
In
pre-Omicron
era,
humoral
SARS-CoV-2
immunity
decreased
three
contacts
further
exposure.
While
neutralization
was
significantly
lower
than
wildtype
(p
<
0.01),
infections
yet
mild
moderate.
Additional
exposures
improved
IgG
levels
0.01)
0.01).
However,
this
effect
less
intense
in
particularly
pancreaticobiliary
neoplasms
(PBN;
p
0.04),
immunodeficiency
0.05),
and/or
under
conventional
chemotherapy
0.05).
Pre-Omicron
prevented
severe
clinical
courses
variants
cancer.
PBN,
immunodeficiency,
initial
antigens
triggered
only
reduced
responses.
Thus,
subgroups
could
be
identified
for
whom
booster
vaccinations
are
special
significance.
BMC Infectious Diseases,
Год журнала:
2024,
Номер
24(1)
Опубликована: Апрель 22, 2024
Abstract
Background
The
impact
of
the
constantly
evolving
severe
acute
respiratory
syndrome
coronavirus
2
on
effectiveness
early
disease
2019
(COVID-19)
treatments
is
unclear.
Here,
we
report
characteristics
and
clinical
outcomes
patients
with
COVID-19
treated
a
monoclonal
antibody
(mAb;
presumed
to
be
sotrovimab)
across
six
distinct
periods
covering
emergence
predominance
Omicron
subvariants
(BA.1,
BA.2,
BA.5)
in
England.
Methods
Retrospective
cohort
study
using
data
from
Hospital
Episode
Statistics
database
January
1–July
31,
2022.
Included
received
mAb
delivered
by
National
Health
Service
(NHS)
hospital
as
day-case,
for
which
primary
diagnosis
was
COVID-19.
Patients
were
have
sotrovimab
based
NHS
showing
that
99.98%
COVID-19-mAb-treated
individuals
during
period.
COVID-19-attributable
hospitalizations
reported
overall
subvariant
prevalence.
Subgroup
analyses
conducted
renal
active
cancer.
Results
Among
total
10,096
patients,
1.0%
(
n
=
96)
had
hospitalization,
4.6%
465)
visit
due
any
cause,
0.3%
27)
died
cause
hospitalization
rates
consistent
among
subgroups,
no
significant
differences
observed
predominance.
Conclusions
Levels
deaths
low
mAb-treated
subgroups.
Similar
whilst
BA.1,
BA.5
predominant,
despite
reductions
vitro
neutralization
activity
against
BA.2
BA.5.
Clinical Infectious Diseases,
Год журнала:
2024,
Номер
unknown
Опубликована: Июнь 3, 2024
The
immunocompromised
population
was
disproportionately
affected
by
the
SARS-CoV-2
pandemic.
However,
these
individuals
were
largely
excluded
from
clinical
trials
of
vaccines,
monoclonal
antibodies,
and
small
molecule
antivirals.
While
community
scientists,
researchers,
funding
agencies
have
proven
that
therapeutics
can
be
made
tested
in
record
time,
extending
this
progress
to
vulnerable
medically
complex
start
has
been
a
missed
opportunity.
Here
we
advocate
it
is
paramount
plan
for
future
pandemics
investing
specific
trial
infrastructure
prepared
when
need
arises.
BMC Infectious Diseases,
Год журнала:
2024,
Номер
24(1)
Опубликована: Июнь 6, 2024
Abstract
This
single-centre
retrospective
cohort
study
reports
on
the
results
of
a
descriptive
(non-comparative)
early
initiation
antivirals
and
combined
monoclonal
antibody
therapy
(mAbs)
in
48
severely
immunocompromised
patients
with
COVID-19.
The
assessed
outcomes
duration
viral
shedding.
started
(ECT)
median
2
days
(interquartile
range
[IQR]:
1–3
days)
after
diagnosis
SARS-CoV-2
infection.
Except
for
1
patient
who
died
due
COVID-19-related
respiratory
failure,
had
their
first
negative
nasopharyngeal
swab
result
11
(IQR:
6–17
starting
therapy.
There
were
no
severe
side
effects.
During
follow-up
period
512
413–575
days),
6
(12.5%)
16
(33.3%)
admitted
to
hospital.
Moreover,
12
(25%)
diagnosed
reinfection
245
138–401
treatment.
No
relapses
reported.
Although
there
was
comparison
group,
these
compare
favourably
COVID-19
reported
literature.
Journal of Clinical Medical Research,
Год журнала:
2025,
Номер
unknown, С. 1 - 28
Опубликована: Янв. 31, 2025
The
emergence
of
new
variants
concern
in
immunocompromised
persons
with
SARS-CoV-2,
particularly
those
mutations
the
spike
protein,
has
complicated
treatment
strategies.
Some
Therapies
focused
only
on
viral
clearance
effects
and
not
major
clinical
outcomes.
As
virus
continues
to
evolve,
development
broad-spectrum
therapies,
along
personalized
approaches
treatment,
will
be
crucial
managing
COVID-19
.
After
first
year
period
which
several
treatments
were
employed
early
intervention
strategies,
including
use
antiretrovirals
monoclonal
antibodies,
have
emerged
as
promising
mitigate
severity
fragile
individuals
prevent
disease
progression,
hospitalization
death
even
recent
time
less
aggressive
SARS-CoV-2
variants.
Guidelines,
high-quality
data
for
combination
exploiting
antivirals
neutralizing
antibodies
do
exist
outpatient
setting,
especially
severe
individuals.
Nevertheless,
studies
attempted
investigate
efect
this
approach
although
these
are
often
observational
without
control
groups,
generally
no
adverse
reactions
from
therapy
been
reported.
potential
efficacy
therapy,
based
an
antiviral
plus
a
antibody,
severely
patients
is
matter
literature
debate
scientific
word.
To
date,
information
concerning
using
combined
therapies
limited.
In
Literature
Review
we
explain
Last
variant
updates
vulnerable
Sars-Cov-2.
Infectious Diseases,
Год журнала:
2025,
Номер
unknown, С. 1 - 10
Опубликована: Янв. 3, 2025
Background
Although
recommended
isolation
periods
for
Coronavirus
disease
2019
(COVID-19)
have
been
shortened
as
the
pandemic
has
subsided,
prolonged
Severe
Acute
Respiratory
Syndrome-Coronavirus-2
(SARS-CoV-2)
shedding
remains
common
in
immunocompromised
patients.
This
study
estimated
probability
of
viral
clearance
these
patients
based
on
elapsed
days
and
specific
risk
factors.
Journal of Antimicrobial Chemotherapy,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 13, 2025
Abstract
Background
Persistent
COVID-19
(pCOVID-19)
in
immunocompromised
patients
is
characterized
by
unspecific
symptoms
and
pulmonary
infiltrates
due
to
ongoing
severe
acute
respiratory
syndrome
coronavirus-2
(SARS-CoV-2)
replication.
Treatment
options
remain
unclear,
leading
different
approaches,
including
combination
therapy
extended
durations.
The
purpose
of
this
study
was
assess
the
efficacy
safety
antiviral
therapies
for
pCOVID-19
since
Omicron
surge.
Methods
We
searched
MEDLINE
Scopus
from
1
January
2022
6
August
2024
cohort
studies
case
series
on
nirmatrelvir/ritonavir,
remdesivir,
ensitrelvir
molnupiravir.
Evidence
certainty
rated
using
Grading
Recommendations
Assessment,
Development,
Evaluation
outcomes
viral
clearance,
recurrence/relapse,
mortality,
adverse
events
(AEs)
symptom
resolution.
Results
Thirteen
involving
127
cases
were
included.
very
low.
In
with
at
least
two
direct
agents,
clearance
79%,
a
16%
recurrence
rate.
All-cause
mortality
9%,
6%
while
SARS-CoV-2
positive.
47
cases,
AEs
reported
11%.
Symptom
resolution
ranged
3
days
studies.
one
agent
passive
immunization,
89%,
an
11%
rate
no
deaths.
four
documented
observed.
monotherapy,
100%,
15%
One
death,
unrelated
SARS-CoV-2,
occurred.
12
Conclusions
Based
low
evidence,
combining
immunization
resulted
high
rates
few
recurrences.
occurred
treated
antivirals.
Controlled
are
needed.
